Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 July 2006, Vol. 108, No. 1, pp. 28-37.
Prepublished online as a Blood First Edition Paper on March 7, 2006; DOI 10.1182/blood-2006-01-0092.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2006-01-0092v1
108/1/28    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hughes, T.
Right arrow Articles by Goldman, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hughes, T.
Right arrow Articles by Goldman, J. M.
Related Collections
Right arrow Neoplasia
Right arrow Oncogenes and Tumor Suppressors
Right arrow Reviews in Translational Hematology
Right arrow Clinical Trials and Observations
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

REVIEW IN TRANSLATIONAL HEMATOLOGY

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

Timothy Hughes, Michael Deininger, Andreas Hochhaus, Susan Branford, Jerald Radich, Jaspal Kaeda, Michele Baccarani, Jorge Cortes, Nicholas C. P. Cross, Brian J. Druker, Jean Gabert, David Grimwade, Rüdiger Hehlmann, Suzanne Kamel-Reid, Jeffrey H. Lipton, Janina Longtine, Giovanni Martinelli, Giuseppe Saglio, Simona Soverini, Wendy Stock, and John M. Goldman

From the Institute of Medical and Veterinary Science, Adelaide, Australia; Department of Hematology/Medical Oncology, Oregon Health & Science University Cancer Institute, Portland, OR; Faculty of Clinical Medicine Mannheim, University of Heidelberg, Mannheim, Germany; Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Haematology, Imperial College at Hammersmith Hospital, London, United Kingdom; Institute of Hematology and Medical Oncology "Seragnoli," University of Bologna, Italy; Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, TX; National Genetics Reference Laboratory, University of Southampton, Salisbury, United Kingdom; Assistance Publique des Hopitaux de Marseille (APHM) and Equipe de Recherche Technologique (ERT), University de la Mediterranée, Marseille, France; Department of Medical and Molecular Genetics, King's College, London, United Kingdom; Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada; Department of Pathology, Brigham and Women's Hospital, Boston, MA; Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy; Department of Medicine, University of Chicago, Chicago, IL; and the Hematology Branch, National Heart, Lung & Blood Institute, National Institutes of Health (NIH), Bethesda, MD.

The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase inhibitors may prove superior to IM. Real-time quantitative polymerase chain reaction (RQ-PCR) provides an accurate measure of the total leukemiacell mass and the degree to which BCR-ABL transcripts are reduced by therapy correlates with progression-free survival. Because a rising level of BCR-ABL is an early indication of loss of response and thus the need to reassess therapeutic strategy, regular molecular monitoring of individual patients is clearly desirable. Here we summarize the results of a consensus meeting that took place at the National Institutes of Health (NIH) in Bethesda in October 2005. We make suggestions for (1) harmonizing the differing methodologies for measuring BCR-ABL transcripts in patients with CML undergoing treatment and using a conversion factor whereby individual laboratories can express BCR-ABL transcript levels on an internationally agreed scale; (2) using serial RQ-PCR results rather than bone marrow cytogenetics or fluorescence in situ hybridization (FISH) for the BCR-ABL gene to monitor individual patients responding to treatment; and (3) detecting and reporting Philadelphia (Ph) chromosome-positive subpopulations bearing BCR-ABL kinase domain mutations. We recognize that our recommendations are provisional and will require revision as new evidence emerges. (Blood. 2006;108:28-37)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
S. Dulucq, S. Bouchet, B. Turcq, E. Lippert, G. Etienne, J. Reiffers, M. Molimard, M. Krajinovic, and F.-X. Mahon
Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
Blood, September 1, 2008; 112(5): 2024 - 2027.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
H. de Lavallade, J. F. Apperley, J. S. Khorashad, D. Milojkovic, A. G. Reid, M. Bua, R. Szydlo, E. Olavarria, J. Kaeda, J. M. Goldman, et al.
Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis
J. Clin. Oncol., July 10, 2008; 26(20): 3358 - 3363.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
D. Meirow, I. Hardan, J. Dor, E. Fridman, S. Elizur, H. Ra'anani, E. Slyusarevsky, N. Amariglio, E. Schiff, G. Rechavi, et al.
Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients
Hum. Reprod., May 1, 2008; 23(5): 1007 - 1013.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
G. Wertheim and A. Bagg
Nucleophosmin (NPM1) Mutations in Acute Myeloid Leukemia: An Ongoing (Cytoplasmic) Tale of Dueling Mutations and Duality of Molecular Genetic Testing Methodologies
J. Mol. Diagn., May 1, 2008; 10(3): 198 - 202.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
F. Palandri, I. Iacobucci, F. Castagnetti, N. Testoni, A. Poerio, M. Amabile, M. Breccia, T. Intermesoli, F. Iuliano, G. Rege-Cambrin, et al.
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-{alpha}: 5-year outcome
Haematologica, May 1, 2008; 93(5): 770 - 774.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
T. O'Hare, C. A. Eide, J. W. Tyner, A. S. Corbin, M. J. Wong, S. Buchanan, K. Holme, K. A. Jessen, C. Tang, H. A. Lewis, et al.
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib
PNAS, April 8, 2008; 105(14): 5507 - 5512.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
L. K. Kenealy, C. B. Christenson, and C. B. Williams
Current Therapies for Chronic Myeloid Leukemia
Journal of Pharmacy Practice, April 1, 2008; 21(2): 116 - 125.
[Abstract] [PDF]


Home page
J. Mol. Diagn.Home page
J. Laudadio, M. W.N. Deininger, M. J. Mauro, B. J. Druker, and R. D. Press
An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Chronic Myeloid Leukemia Patients Undergoing Kinase Inhibitor Therapy
J. Mol. Diagn., March 1, 2008; 10(2): 177 - 180.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W. Deenik, B. van der Holt, G. E. G. Verhoef, W. M. Smit, M. J. Kersten, H. C. Kluin-Nelemans, L. F. Verdonck, A. Ferrant, A. V. M. B. Schattenberg, J. J. W. M. Janssen, et al.
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia
Blood, March 1, 2008; 111(5): 2581 - 2588.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Kantarjian, C. Schiffer, D. Jones, and J. Cortes
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods
Blood, February 15, 2008; 111(4): 1774 - 1780.
[Full Text] [PDF]


Home page
haematolHome page
M. Baccarani, F. Pane, and G. Saglio
Monitoring treatment of chronic myeloid leukemia
Haematologica, February 1, 2008; 93(2): 161 - 169.
[Full Text] [PDF]


Home page
haematolHome page
T. Lundan, V. Juvonen, M. C. Mueller, S. Mustjoki, T. Lakkala, V. Kairisto, A. Hochhaus, S. Knuutila, and K. Porkka
Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia
Haematologica, February 1, 2008; 93(2): 178 - 185.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
T. Ernst, P. Erben, M. C. Muller, P. Paschka, T. Schenk, J. Hoffmann, S. Kreil, P. La Rosee, R. Hehlmann, and A. Hochhaus
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib
Haematologica, February 1, 2008; 93(2): 186 - 192.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
G. Saglio, F. Pane, and G. Martinelli
State-of-the-art Monitoring for Patients with Chronic Myeloid Leukemia
ASCO Educational Book, January 1, 2008; 2008(1): 313 - 317.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
M. W.N. Deininger
Imatinib Resistance and the Difficulty of Eradicating Leukemia Stem Cells
ASCO Educational Book, January 1, 2008; 2008(1): 318 - 323.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. D. Press, C. Galderisi, R. Yang, C. Rempfer, S. G. Willis, M. J. Mauro, B. J. Druker, and M. W.N. Deininger
A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response
Clin. Cancer Res., October 15, 2007; 13(20): 6136 - 6143.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. M. Goldman
How I treat chronic myeloid leukemia in the imatinib era
Blood, October 15, 2007; 110(8): 2828 - 2837.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. O'Hare, C. A. Eide, and M. W. N. Deininger
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Blood, October 1, 2007; 110(7): 2242 - 2249.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
E. Callet-Bauchu, G. Salles, S. Gazzo, S. Dalle, F. Berger, and S. Hayette
Identification of a novel e8/a4 BCR/ABL fusion transcript in a case of a transformed Sezary syndrome
Haematologica, September 1, 2007; 92(9): 1277 - 1278.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
T. Zhang, S. Grenier, B. Nwachukwu, C. Wei, J. H. Lipton, S. Kamel-Reid, and the Association for Molecular Pathology Hematopath
Inter-Laboratory Comparison of Chronic Myeloid Leukemia Minimal Residual Disease Monitoring: Summary and Recommendations
J. Mol. Diagn., September 1, 2007; 9(4): 421 - 430.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
E. S. Winn-Deen, B. Helton, R. Van Atta, W. Wong, J. Peralta, J. Wang, G. J. Tsongalis, D. Belloni, D. Chan, J. R. Eshleman, et al.
Development of an Integrated Assay for Detection of BCR-ABL RNA
Clin. Chem., September 1, 2007; 53(9): 1593 - 1600.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
C. A. Schiffer
BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia
N. Engl. J. Med., July 19, 2007; 357(3): 258 - 265.
[Full Text] [PDF]


Home page
BloodHome page
C. A. Schiffer
What if conventional-dose imatinib fails?
Blood, June 15, 2007; 109(12): 5068 - 5069.
[Full Text] [PDF]


Home page
Cancer Res.Home page
G. Volpe, A. Cignetti, C. Panuzzo, M. Kuka, K. Vitaggio, M. Brancaccio, G. Perrone, M. Rinaldi, G. Prato, M. Fava, et al.
Alternative BCR/ABL Splice Variants in Philadelphia Chromosome-Positive Leukemias Result in Novel Tumor-Specific Fusion Proteins that May Represent Potential Targets for Immunotherapy Approaches
Cancer Res., June 1, 2007; 67(11): 5300 - 5307.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. V. Jovanovic, J. Score, K. Waghorn, D. Cilloni, E. Gottardi, G. Metzgeroth, P. Erben, H. Popp, C. Walz, A. Hochhaus, et al.
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia
Blood, June 1, 2007; 109(11): 4635 - 4640.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Hehlmann, U. Berger, M. Pfirrmann, H. Heimpel, A. Hochhaus, J. Hasford, H.-J. Kolb, T. Lahaye, O. Maywald, A. Reiter, et al.
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia
Blood, June 1, 2007; 109(11): 4686 - 4692.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Picard, K. Titier, G. Etienne, E. Teilhet, D. Ducint, M.-A. Bernard, R. Lassalle, G. Marit, J. Reiffers, B. Begaud, et al.
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Blood, April 15, 2007; 109(8): 3496 - 3499.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
I. Iacobucci, L. Galletti, M. Amabile, S. Soverini, M. Baccarani, and G. Martinelli
Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio
Haematologica, March 1, 2007; 92(3): 429 - 430.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Hertzberg and D. McDonald
Optimizing fusion transcript monitoring in CML
Blood, March 1, 2007; 109(5): 2263 - 2263.
[Full Text] [PDF]


Home page
BloodHome page
T. Hughes, S. Branford, and J. M. Goldman
Response: Reliability of PCR for BCR-ABL transcripts
Blood, March 1, 2007; 109(5): 2263 - 2264.
[Full Text] [PDF]


Home page
ASH Education BookHome page
S. Branford
Chronic Myeloid Leukemia: Molecular Monitoring in Clinical Practice
Hematology, January 1, 2007; 2007(1): 376 - 383.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Rousselot, F. Huguet, D. Rea, L. Legros, J. M. Cayuela, O. Maarek, O. Blanchet, G. Marit, E. Gluckman, J. Reiffers, et al.
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
Blood, January 1, 2007; 109(1): 58 - 60.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. A. Bradeen, C. A. Eide, T. O'Hare, K. J. Johnson, S. G. Willis, F. Y. Lee, B. J. Druker, and M. W. Deininger
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations
Blood, October 1, 2006; 108(7): 2332 - 2338.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
S. K. Kathula, S.-C. Chu, J.-L. Tang, C.-C. Li, C. L. Sawyers, M. Talpaz, and E. Bleickardt
Dasatinib in chronic myelogenous leukemia.
N. Engl. J. Med., September 7, 2006; 355(10): 1062 - 1063.
[Full Text] [PDF]


Home page
ASH Education BookHome page
T. Hughes
ABL Kinase Inhibitor Therapy for CML: Baseline Assessments and Response Monitoring
Hematology, January 1, 2006; 2006(1): 211 - 218.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
M. J. Mauro
Defining and Managing Imatinib Resistance
Hematology, January 1, 2006; 2006(1): 219 - 225.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
J. F. Apperley
Managing the Patient with Chronic Myeloid Leukemia Through and After Allogeneic Stem Cell Transplantation
Hematology, January 1, 2006; 2006(1): 226 - 232.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access